dexrazoxane has been researched along with Cardiac Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Aghdam, M; Crooks, BN; Giacomantonio, N; Grandy, SA; Heinze-Milne, S; Johnston, WJ; Keats, MR; Kendall, SJ; Langley, JE; Mulvagh, SL | 1 |
| Hasinoff, BB; Patel, D; Wu, X | 1 |
| Huang, Y; Li, F; Li, L; Ma, L; Nie, X; Qin, W; Yi, M; Yuan, X; Zhang, P | 1 |
| Andelfinger, G; Ansari, M; Bertout, L; Drouin, S; Elbared, J; Krajinovic, M; Kutok, JL; Laverdière, C; Lipshultz, SE; Neuberg, DS; Raboisson, MJ; Rezgui, A; Sallan, SE; Silverman, LB; Sinnett, D | 1 |
| Alexander, S; Dupuis, LL; Gupta, A; Mertens, L; Nathan, PC; Shaikh, F | 1 |
| Chen, JJ; Middlekauff, HR; Nguyen, KL; Wu, PT | 1 |
| Cheng, G; GenJin, Y; Jie, L; Jin, L; JinLu, H; LiLi, W; QuanJun, Y; Run, G; Yan, H; YongLong, H | 1 |
3 review(s) available for dexrazoxane and Cardiac Diseases
| Article | Year |
|---|---|
The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review.
Topics: Anthracyclines; Cancer Survivors; Cardiotoxicity; Dexrazoxane; Heart Diseases; Humans; Neoplasms; Survivors | 2022 |
Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Bias; Cardiotonic Agents; Child; Dexrazoxane; Disease-Free Survival; Evidence-Based Medicine; Heart; Heart Diseases; Humans; Incidence; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Risk; Treatment Outcome | 2016 |
Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
Topics: Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Exercise; Exercise Therapy; Heart Diseases; Humans; Neoplasms; Survivors | 2017 |
1 trial(s) available for dexrazoxane and Cardiac Diseases
| Article | Year |
|---|---|
Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Doxorubicin; Female; Genetic Predisposition to Disease; Heart Diseases; Heterozygote; Homozygote; Humans; Infant; Male; Multidrug Resistance-Associated Proteins; Myocardial Contraction; Nitric Oxide Synthase Type III; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protective Factors; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Young Adult | 2016 |
3 other study(ies) available for dexrazoxane and Cardiac Diseases
| Article | Year |
|---|---|
The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Topics: Animals; Animals, Newborn; Cardiotoxicity; Cells, Cultured; Dexrazoxane; DNA Topoisomerases, Type II; Doxorubicin; Female; Heart Diseases; Male; Myocytes, Cardiac; Primary Cell Culture; Rats, Sprague-Dawley; Signal Transduction; Time Factors; Topoisomerase II Inhibitors | 2020 |
Dexrazoxane ameliorates radiation-induced heart disease in a rat model.
Topics: Animals; Apoptosis; Dexrazoxane; Heart; Heart Diseases; Male; Mice; Mice, Nude; Protective Agents; Radiation Injuries, Experimental; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2021 |
Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Doxorubicin; Glucose; Heart Diseases; Lipid Metabolism; Male; Metabolome; Metabolomics; Mice; Nuclear Magnetic Resonance, Biomolecular; Oxidation-Reduction | 2017 |